Filing Flows › Royalty Pharma (RPRX) › Q2 2026 › vs Q1 2026
Royalty Pharma (RPRX) Q2 2026 vs Q1 2026 (quarter over quarter)
Royalty Pharma's revenue rose $43.6M (+7%) from $631M in Q1 2026 to $674M in Q2 2026. The biggest changes: Income from financial royalty assets +$43.0M (+7%); Other royalty income and revenues +$530K (+1%). Operating margin 19.7% against 89.3% (-69.5 pts).
Royalty Pharma, Q2 2026: revenue $674M (+16% year over year), operating margin 19.7%, net earnings $17.9M, operating cash flow $728M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Operating margin | 19.7% | 89.3% | -69.5 pts |
| Net margin | 2.7% | 46.7% | -44.1 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Income from financial royalty assets | $638M | $595M | $43.0M | +7% |
| Other royalty income and revenues | $36.1M | $35.6M | $530K | +1% |
| Revenue | $674M | $631M | $43.6M | +7% |
| Operating profit | $133M | $563M | −$430M | -76% |
| Costs & expenses | $541M | $67.5M | $473M | +701% |
| Pre-tax earnings | $81.5M | $468M | −$387M | -83% |
| Other expense, net | $51.6M | $94.8M | −$43.1M | -46% |
| Net earnings | $17.9M | $295M | −$277M | -94% |
| Minority interests | $63.6M | $174M | −$110M | -63% |
| Depreciation | $1.3M | $1.2M | $123K | +11% |
| Share-based compensation | $107M | $122M | −$14.9M | -12% |
| Working capital & other | $602M | $300M | $302M | +100% |
| Operating cash flow | $728M | $718M | $10.2M | +1% |
Questions
How much did Royalty Pharma's revenue grow quarter over quarter in Q2 2026?
Royalty Pharma's revenue rose $43.6M (+7%) from $631M in Q1 2026 to $674M in Q2 2026.
What drove Royalty Pharma's revenue change in Q2 2026?
Income from financial royalty assets +$43.0M (+7%); Other royalty income and revenues +$530K (+1%).